Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

Abstract: Provided herein are anti-CD30 antibody-drug conjugates and methods of using the same to modulate the immune response in a subject.

Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

Abstract: The invention provides methods and compositions for modulating the immune response in a subject, such as decreasing the activity of CD30+ T regulatory cells and increasing the ratio of CD8+ T cells to CD30+ T regulatory cells, through administration of antibody drug-conjugates that bind to CD30. The invention also provides articles of manufacture or kits comprising said antibody drug-conjugates that bind to CD30 for modulating the immune response.

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Abstract: Glue bottle anti-clog caps are provided. The anti-clog cap has a body with a mounting section for attaching the body to a glue bottle. The body of the anti-clog cap has a dispensing section that includes a central lumen extending from the second mounting end. The body of the anti-clog cap also has a tip section with a support rib protruding from an outlet of the dispensing section. The tip has a tip plug protruding from the support rib. The anti-clog cap has a nozzle that mates to the body and a tip orifice aligned with the tip plug of the body. The tip section is configured to allow the free flow of glue through the cap. The nozzle can rotate between an open and closed position. In the closed position the tip plug can extend into the tip orifice thereby preventing the flow of glue.

Abstract: The invention provides methods and compositions for modulating the immune response in a subject, such as decreasing the activity of CD30+ T regulatory cells and increasing the ratio of CD8+ T cells to CD30+ T regulatory cells, through administration of antibody drug-conjugates that bind to CD30. The invention also provides articles of manufacture or kits comprising said antibody drug-conjugates that bind to CD30 for modulating the immune response.

Abstract: Glue bottle anti-clog caps are provided. The anti-clog cap has a body with a mounting section for attaching the body to a glue bottle. The body of the anti-clog cap has a dispensing section that includes a central lumen extending from the second mounting end. The body of the anti-clog cap also has a tip section with a support rib protruding from an outlet of the dispensing section. The tip has a tip plug protruding from the support rib. The anti-clog cap has a nozzle that mates to the body and a tip orifice aligned with the tip plug of the body. The tip section is configured to allow the free flow of glue through the cap. The nozzle can rotate between an open and closed position. In the closed position the tip plug can extend into the tip orifice thereby preventing the flow of glue.

Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

Abstract: The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin.